L'intérêt à découvert pour Alector donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Alector. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Alector (NASDAQ:ALEC) Stock, Rapport sur les intérêts à découvert

Alector

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Alector Inc

Macro Economic Events

News

Econ #s

Economics

USA API Weekly Crude Oil Stock A Draw Of 5.935M Barrels Vs A Build Of 0.250M Barrels Est.; Build Of 4.753M Barrels Prior

The Q1 earnings report for Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) was released on Tuesday, November 26, 2024 at 04:01 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Nutanix beat estimated earnings by 31.0%, reporting an EPS of $0.42 versus an estimate of $0.32.
Revenue was up $79.90 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.07 in the last quarter, resulting in a 20.0% increase share price change the following day.
Here's a look at Nutanix's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.16</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.28</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>536.94M</td>
<td>516.18M</td>
<td>551.34M</td>
<td>501.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>547.95M</td>
<td>524.58M</td>
<td>565.23M</td>
<td>511.05M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Nutanix <a href="https://www.benzinga.com/quote/NTNX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

NTNX

Nutanix: Q1 Earnings Insights

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) reported its Q3 earnings results on Tuesday, November 26, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Autodesk beat estimated earnings by 2.0%, reporting an EPS of $2.17 versus an estimate of $2.12.
Revenue was up $156.00 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company beat on EPS by $0.15 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Autodesk's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2</td>
<td>1.77</td>
<td>1.95</td>
<td>1.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.15</td>
<td>1.87</td>
<td>2.09</td>
<td>2.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.48B</td>
<td>1.39B</td>
<td>1.43B</td>
<td>1.39B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.50B</td>
<td>1.42B</td>
<td>1.47B</td>
<td>1.41B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Autodesk <a href="https://www.benzinga.com/quote/ADSK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

Earnings Breakdown: Autodesk Q3

Guidance

Nutanix Sees Q2 Revenue $635M-$645M.

MTEM

Molecular Templates Received Nasdaq Notices For Non-Compliance Due To Delinquent Filing Of Q3 Report And Minimum Bid Price Below $1, With Deadlines To Regain Compliance By May 2025 And Potential Delisting Consequences; The Company Has Until January 24, 2025 To Submit A Plan To Regain Compliance With Respect To The Delinquent Filing

Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) released its Q1 earnings on Tuesday, November 26, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Nutanix beat estimated earnings by 31.0%, reporting an EPS of $0.42 versus an estimate of $0.32.
Revenue was up $79.90 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.07 in the last quarter, resulting in a 20.0% increase share price change the following day.
Here's a look at Nutanix's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.16</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.28</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>536.94M</td>
<td>516.18M</td>
<td>551.34M</td>
<td>501.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>547.95M</td>
<td>524.58M</td>
<td>565.23M</td>
<td>511.05M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Nutanix <a href="https://www.benzinga.com/quote/NTNX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nutanix Earnings Analysis: Q1 Recap

The Q3 earnings report for Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) was released on Tuesday, November 26, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Autodesk beat estimated earnings by 2.0%, reporting an EPS of $2.17 versus an estimate of $2.12.
Revenue was up $156.00 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.15 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Autodesk's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2</td>
<td>1.77</td>
<td>1.95</td>
<td>1.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.15</td>
<td>1.87</td>
<td>2.09</td>
<td>2.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.48B</td>
<td>1.39B</td>
<td>1.43B</td>
<td>1.39B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.50B</td>
<td>1.42B</td>
<td>1.47B</td>
<td>1.41B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Autodesk <a href="https://www.benzinga.com/quote/ADSK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Autodesk Q3

The Q3 earnings report for Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) was released on Tuesday, November 26, 2024 at 04:15 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Guess missed estimated earnings by -8.0%, reporting an EPS of $0.34 versus an estimate of $0.37.
Revenue was up $87.35 million from the same period last year.
<h3>Earnings History Overview</h3>
In the previous quarter, the company missed on EPS by $0.02, resulting in a 1.0% increase change in the share price the following day.
Here's a look at Guess's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>-0.40</td>
<td>1.56</td>
<td>0.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.42</td>
<td>-0.27</td>
<td>2.01</td>
<td>0.49</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>731.01M</td>
<td>574.64M</td>
<td>855.54M</td>
<td>656.03M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>732.56M</td>
<td>591.94M</td>
<td>891.05M</td>
<td>651.17M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Guess <a href="https://www.benzinga.com/quote/GES/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Guess Q3

Gold producer Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) sold its Éléonore mine in Quebec Tuesday to London-based Dhilmar for $795 million in cash.
The sale follows Newmont's strategy to divest non-core assets following its <a href="https://www.benzinga.com/markets/equities/23/05/32385120/newmont-takeovers-newcrest-in-a-largest-ever-gold-industry-deal">milestone acquisition of Newcrest Mining</a> in 2023.
"When we announced the acquisition of Newcrest, we committed to generating at least $2 billion in cash through portfolio optimization. With this announced sale, we have exceeded that target by more than $1.5 billion," <a href="https://www.newmont.com/investors/news-release/news-details/2024/Newmont-Announces-Agreement-for-Sale-of-lonore-for-795-Million-in-Cash/default.aspx">said</a> Newmont CEO Tom Palmer. With this transaction, asset sales generated around $3.6 billion year-to-date.
Located in the Eeyou Istchee/James Bay region of Quebec, Éléonore is a notable underground gold mine producing approximately 215,000 ounces annually. Operational since 2014, the mine's location in an attractive jurisdiction makes it a quality addition to Dhilmar's portfolio.
Still, Newmont is set to <a href="https://www.benzinga.com/news/large-cap/24/02/37287732/gold-miner-newmont-looks-to-sell-assets-reduce-8b-debt-load">focus on Tier 1 assets</a> —mines with long lives, substantial reserves, and strong cash flow potential. To prioritize these operations and expand margins, the company sold several assets, including Akyem in Ghana (for $1 billion) and Musselwhite in Canada (for $850 million).
While Newmont bolstered its reserves through a timely acquisition, its main rival, Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>), has f<a href="https://www.benzinga.com/news/24/09/40915786/barrick-forecasts-strong-organic-growth-by-2030-ceo-bristow-touts-undervaluation">ocused on organic growth</a>. Its recent update of resource estimates for its Fourmile project showed 1.4 million ounces of indicated resources and 6.4 million ounces of inferred resources, with gold grades as high as 14.1 g/t.
"Fourmile is a truly world-class asset, comparable to Barrick's foundational Goldstrike deposit," said Mark Bristow, Barrick's CEO. Like Newmont, Barrick prefers resource expansion within top jurisdictions despite Bristow's legendary ability to navigate political issues in emerging markets.
The divergence in strategy showcases each company's adaptation to industry challenges. Reducing exposure to non-core assets for Newmont supports balance sheet resilience and shareholder returns. Barrick, however, focuses on leveraging existing assets like Fourmile and the $1 billion Goldrush project, which aims for commercial production by 2026.
Despite a recent pullback, gold remains one of the year&#8217;s best-performing assets, rising 27.5%. However, both Newmont and Barrick came nowhere near such gains, with the former gaining 3.79% and later dropping 1.12% year-to-date.
Looking ahead, Barrick plans a pre-feasibility study for Fourmile in 2025 and is advancing the Reko Diq copper-gold project in Pakistan. Meanwhile, Newmont continues to refine its portfolio, aiming to fortify its position in key markets and invest in high-margin assets.
Read Next:&nbsp; 
<ul>
<li><a href="https://www.benzinga.com/24/11/42166102/anglo-american-sells-coal-portfolio-for-38-billion-continues-restructuring">Anglo American Sells Coal Portfolio For $3.8 Billion</a></li>
</ul>
Image via Shutterstock.

Commodities

Asset Sales

GOLD

Newmont Sells Mine For $795 Million, Barrick Expands Reserves; Top Miners Unfazed By Underperformance

WIIM

3D Systems shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.

Biotech

General

PTCT

PTC Therapeutics Says CardinALS Trial Of Utreloxastat In ALS Patients Failed To Meet Primary And Secondary Efficacy Endpoints

Valens Semiconductor shares are trading higher after the company announced a $10 million share repurchase program.

CrowdStrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) reported third-quarter financial results after the market close on Tuesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/24/11/b42200747/crowdstrike-reports-third-quarter-fiscal-year-2025-financial-results">from the report</a>.
Q3 Earnings: CrowdStrike reported third-quarter revenue of $1.01 billion, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $982.36 million.&nbsp;The cybersecurity company reported adjusted earnings of $93 cents per share, beating analyst estimates of 81 cents per share.
CrowdStrike has exceeded analyst estimates in every quarter since going public in 2019, according to data from&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 29% year-over-year. Annual recurring revenue increased 27% year-over-year to $4.02 billion after the company added $153 million of net new ARR in the quarter. 
Net cash generated from operations was $326.1 million and free cash flow came in at $230.6 million. The company ended the quarter with $4.26 billion in cash, equivalents and short-term investments.
&#8220;CrowdStrike surpassed $4 billion in ending ARR in the quarter — the fastest and only pure play cybersecurity software company to reach this reported milestone — as our single platform approach and trailblazing innovation continue to resonate at-scale,&#8221; said George Kurtz, co-founder, president and CEO of CrowdStrike.
&#8220;With over&nbsp;97%&nbsp;gross retention, customers remain committed to the technological superiority of the Falcon platform and the benefits of cybersecurity consolidation. Accelerating module adoption and customers embracing our transformational Falcon Flex subscription model give us confidence in CrowdStrike&#8217;s bright future as cybersecurity&#8217;s AI platform of record.&#8221;
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42198904/ai-jesus-hears-confessions-in-switzerland-has-artificial-intelligence-gone-too-far">AI Jesus Hears Confessions In Switzerland: Has Artificial Intelligence Gone Too Far?</a>
CrowdStrike provided an update on customers who were impacted by the <a href="https://www.benzinga.com/news/24/07/39873706/crowdstrike-outage-impacted-less-than-1-of-windows-devices-but-still-managed-to-wreak-havoc-report">global IT outage</a> in July due to a defect in a CrowdStrike content update. The company said last quarter that it was extending commitment packages to impacted customers. CrowdStrike said Tuesday that it saw &#8220;incredible success&#8221; with customer packages as customers embraced the program and chose to deepen their relationships with the company.
Guidance: CrowdStrike expects fourth-quarter revenue to be between $1.029 billion and $1.035 billion versus estimates of $1.03 billion. The company anticipates fourth-quarter adjusted earnings of 84 cents to 86 cents per share versus estimates of 86 cents per share.
CrowdStrike also raised its fiscal year 2025 guidance. The company now expects full-year revenue of $3.923 billion to $3.931 billion versus estimates of $3.897 billion. The company expects full-year earnings to be in the range of $3.74 to $3.76 per share versus estimates of $3.63 per share.
Management will hold a conference call with analysts and investors at 5 p.m. ET to further discuss the company's quarterly results.
CRWD Price Action: <a href="https://www.benzinga.com/quote/CRWD" target="_blank" rel="noreferrer noopener">CrowdStrike shares</a> were down 1.45% after hours, trading at $359 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Fed Minutes Reveal &#8216;Confidence&#8217; In Inflation Reduction, Yet Flag Divergent Views On Interest Rate Path Ahead</a></li>
</ul>
Photo: Shutterstock.

After-Hours Center

Movers

Tech

CRWD

CrowdStrike Beats Q3 Earnings, Revenue Estimates; Cybersecurity Company Highlights 'Incredible Success' Retaining Customers Following IT Outage

Wu will oversee the Company's overall operational management while continuing his technology leadership role.

Management

YXT.com Names Yazhou Wu, Its Chief Technology Officer, To The Additional Role Of COO

Buybacks

Valens Adopts $10M Buyback Program

Nutanix Sees FY25 Revenue $2.435B-$2.465B; Non-GAAP Operating Margin 16%-17%; Free Cash Flow $560M-$610M.

Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) reported quarterly earnings of $0.72 per share. The company reported $34.40 million in sales this quarter.

Yxt.Com Group Holding Q3 2024 EPS $0.72, Sales $34.40M

Zu's resignation did not result from any disagreement with the Company. In addition, the board of directors of the Company appointed Zu as the vice chairman of the Board, effective today. Zu will remain with the Company as a director and the vice chairman of the Board.
Lu will continue his role as chairman of the Board.

YXT.com Says Teng Zu Has Resigned From His Position As CEO Due To Personal Reasons, Effective Today; Chairman Xiaoyan Lu Named Also As CEO

NOAH

Noah Holdings Q3 Revenue RMB683.7M, Down 8.8% YoY, Non-GAAP EPADS RMB2.14, Down From RMB3.35 YoY

3D Systems Sees FY24 Revenue $440M-$450M Vs $452.893M Est.

Alector drops 31% as Alzheimer's candidate fails in phase 2 trial

Biggest stock movers Tuesday: PSTX, SMTC, ALEC, LESL, WWD and more

BTIG analyst Thomas Shrader maintained a Buy rating on Alector (ALEC – Research Report) yesterday and set a price target of $5.00. Thomas Shrader h...

Alector's Strategic Innovations and Potential in Neurological Treatments Justify Buy Rating

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating on the shares. The comp...

Alector price target lowered to $7 from $35 at H.C. Wainwright

BTIG lowered the firm's price target on Alector (ALEC) to $5 from $16 and keeps a Buy rating on the shares. The TREM2 activation had little effect ...

Alector price target lowered to $5 from $16 at BTIG

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Alector (ALEC – Research Report). The company's shares closed yes...

TD Cowen Remains a Buy on Alector (ALEC)

Morgan Stanley downgraded Alector (ALEC) to Underweight from Equal Weight with a price target of $3, down from $10, after AL002 did not slow Alzhei...

Alector downgraded to Underweight from Equal Weight at Morgan Stanley

Biggest stock movers Tuesday: PSTX, ARWR, KSS, ALEC, AMGN, EMBC, and more

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today. Graig Suvannavejh's ratin...

Buy Rating Maintained for Alector Despite AL002 Setback, Focus on Promising AL001 and Strong Financials

Mizuho says Alector's (ALEC) top-line Phase 2 results for AL002 in Alzheimer's disease "were non-equivocal, with negative signals on all primary or...

Alector shares may settle in $2.50-$3.50 range, says Mizuho

ALEC

AMGN

ARWR

EMBC

HSAI

LESL

MAXN

PSTX

RHHBF

RHHBY

RHHVF

SMTC

SRPT

Health Care

Press Releases

Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Host Mid-Year Earnings Conference Call

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Participate in Upcoming Healthcare Conferences

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Financing

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

ABBV

HTGC

Absci

Akebia Therapeutics

Aura Biosciences

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Design Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kodiak Sciences

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Neurogene

Prime Medicine

AVITA Medical

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tango Therapeutics

Valneva

Verve Therapeutics

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

Y-mAbs Therapeutics

Zenas BioPharma

Morgan Stanley

BTIG

HC Wainwright & Co.

Stifel

Deutsche Bank

Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.

Comments

Alector

Intérêt court

Alector (NASDAQ:ALEC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL